

Please amend claims 1-3, 5-8, 14 and 16 as follows:

1. (Amended) Recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) [CSF] protein having a sequence shown in Figure 1.

2. (Amended) Human GM-CSF protein having a specific activity of 1×10^7 units/mg in the bone marrow assay, a 15-26 kDa molecular weight and a sequence shown in Figure 1.

3. (Amended) Human GM-CSF protein as claimed in claim 2 which is recombinant GM-CSF protein.

4.4
5. (Amended) Human GM-CSF protein as claimed in
any one of claims 1-3, wherein said protein comprises thr₁₀₀ or
ile₁₀₀ [which has the amino acid sequence shown for CSF-thr in
Fig. 1, or CSF-ile in Fig. 1, or CSF-G in Fig. 1].

6. (Amended) [A] Human GM-CSF protein as claimed
in any one of claims 1-3, wherein said protein has an N-terminus
consisting of ala or met-alay [which contains the amino acid
sequence as shown in Fig. 1 commencing with Ala-Pro ... or
wherein the amino acid sequence commencing Ala-Pro ... is
proceeded by a methionine residue].

b6
7. (Amended) [A] Human GM-CSF protein according
C to any one of claims 1-3, comprising at least one of the group
consisting of ser₃, arg₁₀, ile₃₆, val₄₃, thr₁₁₇ and gly₁₂₇ [which
is a CSF protein corresponding in amino acid sequence to a
naturally occurring CSF, except that one or more amino acids
has been added, substituted or removed without substantially
affecting the biological activity of the natural CSF].

b2
Correl.

b7
8. (Amended) [A] Human GM-CSF protein according
C to any one of claims 1-3, which is a CSF protein having the amino
C acid sequence of a natural CSF except that it is preceded by
a methionine residue.

b3
9. (Amended) A [pharmaceutical] composition
C comprising a human GM-CSF according to any one of claims 1-3, [or
CSF according to claim 1 for use in therapy] in a
pharmaceutically acceptable carrier.

b4
10. (Amended) A [pharmaceutical] composition
C comprising a [recombinant] human GM-CSF according to any one of
claims 1-3, prepared [according to the process of claim 12]
by the steps comprising:

precipitating the GM-CSF protein with ammonium
C GM-CSF
sulfate to form a pellet containing the CSF protein;
resuspending the pellet in a buffered solution
at a pH in the range of about 6 to about 8;